Latest news with #insertion
Business Insider
23-05-2025
- Health
- Business Insider
Cullinan Therapeutics to present new results from REZILIENT1 trial
Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology announced new results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations who have received prior therapy. These data will be presented on Sunday, June 1 at the American Society of Clinical Oncology annual meeting as an oral presentation. As of the December 2024 data cutoff, 244 patients were enrolled in REZILIENT1 and received at least one dose of 100 mg zipalertinib. The overall efficacy population consisted of all patients who received at least one dose of 100 mg zipalertinib and had approximately 8 months of minimum follow-up at data cutoff. Patients had received a median of 2 prior therapies, and 39% of patients had a history of brain metastases. With median follow-up of 9.3 months, zipalertinib demonstrated: In the overall efficacy population, confirmed overall objective response rate was 35% with median duration of response of 8.8 months; in patients with prior platinum-based chemotherapy only, ORR was 40% with mDOR of 8.8 months, consistent with REZILIENT1 Phase 1/2a results; in patients with prior chemo and amivantamab, ORR was 30% with mDOR of 14.7 months; in patients with prior chemo and amivantamab, ORR was 24% with mDOR of 8.5 months and in patients with brain metastases, the ORR was 31% with mDOR of 8.3 months. The safety analysis population included all REZILIENT1 patients who received at least one dose of 100 mg zipalertinib. The results showed that zipalertinib demonstrated a manageable safety profile in this heavily pre-treated patient population, consistent with previously reported data. The most common treatment-related adverse events were paronychia, rash, dermatitis acneiform, dry skin, diarrhea and stomatitis. The majority of TRAEs were grade 1 or 2. The most common grade 3 TRAEs were anemia, pneumonitis and rash, increased alanine aminotransferase, diarrhea, and decreased platelet count.
Yahoo
17-04-2025
- Health
- Yahoo
Via Christi first to perform new heart procedure
WICHITA, Kan. (KSNW) — Via Christi St. Francis is the first hospital to perform a new procedure to treat people with Coronary Artery Disease. The most common cause of heart attacks and strokes is Coronary Artery Disease. It is caused by plaque buildup along the walls of the arteries in the heart. Over time, this causes the arteries to narrow, blocking blood circulation to the heart. Once the disease has progressed far enough, it often requires surgical intervention. One of the treatments for the disease in its advanced stage is angioplasty, which involves the insertion of stents in the artery to restore blood flow. A wire is threaded through the circulatory system, up to the artery, and a small balloon is inflated, which expands a small wire mesh called a stent, that helps hold the artery open and restore blood flow. Surgeons often use techniques that involve scoring or cutting the artery wall to break up calcified deposits, or they use catheters with rotating blades or lasers. Via Christi is participating in the testing of a new device that uses sound waves to break up the deposits. It's called TECTONIC Coronary Artery Disease Intravascular Lithotripsy. The device is produced by Abbott Laboratories, a company that manufactures diagnostic and medical devices, as well as generic pharmaceuticals and other products. Via Christi St. Francis was the first hospital in the nationwide investigational study of Abbott's IVL to successfully treat a patient. Interventional Cardiologist Bassem Chehab, MD, performed the procedure. Ava Jones announces cancer is 99% clear 'Participating in the TECTONIC CAD IVL trial explores a promising new technology that could significantly improve outcomes for patients with severe coronary artery calcification,' says Dr. Chehab, in a news release from Via Christi. 'By participating in the potential of intravascular lithotripsy, we're helping take a vital step towards enhancing patient care and offering more effective treatment options for this challenging condition.' Chehab adds, 'Being able to treat the first patient ever in a novel and groundbreaking technology solidifies the global and national trust in the expertise of Via Christi as a leader in advanced cardiac care regionally and nationally.' The TECTONIC CAD IVL is undergoing clinical trials and is not currently commercially available. It can take 3 to 7 years for a new medical device to successfully complete a clinical trial and receive FDA approval for widespread use. For more information about Ascension Via Christi Cardiology, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
13-02-2025
- Yahoo
Audio-Technica upgrades its cartilage conduction headphones with a big audio boost
When you buy through links on our articles, Future and its syndication partners may earn a commission. Quick Summary The Audio-Technica ATH-CC500BT2 headphones use cartilage conduction technology to transmit sound through each ear's cartilage without block the ear canal. That means they can be worn and enjoyed while also remaining aware of your immediate surroundings. Audio-Technica has finally followed-up its "world's first" cartilage conduction headphones with a new model that promises better sound quality, yet still enables you to hear what's going on in the outside world. The brand has announced the ATH-CC500BT2 pair which, unlike many conventional headphones, provide stereo audio without blocking the ear canal. The open-ear design works by vibrating each ear's cartilage, allowing for sound to be heard without the need for bud insertion or over-ear immersion. And not only does this mean you can remain more aware of your surroundings, but sound leakage is minimised. Indeed, there's a dedicated Limit Sound Leakage Mode that you can enable when in public places. The headphones are wireless, with multipoint Bluetooth connectivity, while battery life is an impressive 20 hours of playback time. A 10-minute quick charge through USB-C can also give you up to 120 minutes of extra life. While there's no active noise cancellation technology on board, of course, there is AI Noise Reduction. That allows your calls to be heard more clearly, with the tech extracting only the speaker's voice from background interference. Voice assistants are supported, including Siri and Google Assistant, and the ATH-CC500BT2 works with Audio-Technica's Connect app for Android and iPhone to provide different soundscapes and modes. The entire band is IPX4 rated so is water resistant against rain and light splashes, while a slight generational redesign means the device is more comfortable to wear for a whole day of use. The Audio-Technica ATH-CC500BT2 headphones are available now, starting at £119 in the UK, €139 in Europe. We're awaiting US and Australian pricing, but at today's exchange rates it equates to around $147 and AU$235 respectively.
